BETブロモドメインは,心不全における転写パウズ放出を媒介する
Priti Anand1, Jonathan D Brown, Charles Y Lin
1Case Cardiovascular Research Institute, Department of Medicine, Case Western Reserve University School of Medicine, and Harrington Heart & Vascular Institute, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.
Cell
|August 6, 2013
まとめ
ブロモドメイン阻害剤BETは,遺伝子発現を調節することにより,心不全の進行を抑制します. この研究は,BETタンパク質を心不全と心臓の改造の治療における重要な治療標的として特定しています.
科学分野:
- 分子生物学は分子生物学である.
- 心血管研究に関する研究.
- エピジェネティクス エピジェネティクス
背景:
- 心不全 (HF) は,複雑な遺伝子調節とクロマチンの変化を伴う.
- ヒストンアセチルトランスフェラーゼとクロマチンハイパーアセチル化は,HFにおける病理的な遺伝子活性化に関与しています.
研究 の 目的:
- 心不全の病原性におけるアセチルライシンリーダータンパク質,特にブロモドメインの役割を調査する.
- BETブロモドメインタンパク質がHFの遺伝子制御に不可欠であるかどうかを判断する.
主な方法:
- HFにおけるBETブロモドメインタンパク質を研究するために,化学遺伝的アプローチを用いた.
- 統合的転写および表遺伝子解析を行った.
- BET阻害が心筋細胞増殖に及ぼす効果を in vitroおよび心臓再構成 in vivoで評価した.
主要な成果:
- HF遺伝子調節におけるBETブロモドメインタンパク質の中心的な役割を確立した.
- BETの阻害は,カルジオミオサイト高縮および病理的な心臓リモデリングを効果的に抑制することを実証しました.
- BETタンパク質は,HF関連遺伝子の重要な一時停止放出因子として作用することを明らかにした.
結論:
- エピジェネティックリーダ,特にBETタンパク質は,HF病原性における転写停止放出に不可欠である.
- BET共活性化タンパク質は,心不全治療の有望な治療標的を代表しています.
関連する概念動画
Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure Drugs: Diuretics
1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Heart Failure Drugs: β-Blockers
2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626


